P-1636. Comparative Effectiveness of Combination Therapy with Nirmatrelvir-Ritonavir and Molnupiravir versus Monotherapy with Molnupiravir or Nirmatrelvir-Ritonavir in Hospitalised COVID-19 Patients: A Target Trial Emulation Study
Abstract
Abstract Background While molnupiravir and nirmatrelvir-ritonavir have demonstrated efficacy in reducing hospitalisation and mortality among unvaccinated, high-risk COVID-19 patients in outpatient settings, their impact on hospitalised adults remains unclear. Preclinical studies and case reports suggest combining these antivirals may reduce viral shedding and enhance survival.Baseline characteristics of eligible COVID-19 patients after the inverse probability of treatment weighting (IPTW)SMD=Standardised mean difference; SD=Standard deviation; IQR = interquartile range; CCI=Charlson Comorbidity Index; ICU=Intensivecare units;†SMD
Fields of Study & Subjects
COVID-19 Clinical Research Studies
SARS-CoV-2 and COVID-19 Research
Respiratory viral infections research
Publication details
- Journal / source
- Open Forum Infectious Diseases
- Volume
- 13
- Issue
- Supplement_1
- Publication date
- 1 January 2026
- Language
- EN